Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has received two new patents from the European Patent Office, enhancing its intellectual property portfolio. The patents include: European Patent No. 3668382, which safeguards a method for estimating fat content using a single thermoacoustic measurement, and European Patent No. 3661416, which protects a method using multiple measurements. These developments aim to advance ENDRA's TAEUS® technology, targeting clinical needs in liver disease assessment, and expand its existing portfolio of 89 patents.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced a strategic shift in its regulatory approach for the TAEUS System, designed to assess fatty liver tissue, now pursuing the De Novo pathway instead of a 510(k) application. This decision follows constructive discussions with the FDA, aiming for enhanced market claims. The De Novo process allows for a unique product classification, setting a higher standard for the TAEUS System. The company plans to withdraw its current 510(k) application and focus on limited confirmatory clinical data needed for the De Novo submission, expected to foster competitive advantages.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has received Institutional Review Board approval for a clinical study of its Thermo Acoustic Enhanced UltraSound (TAEUS) device at Shanghai General Hospital, targeting Non-Alcoholic Fatty Liver Disease (NAFLD). This marks ENDRA's first clinical research partnership in Asia, offering strategic entry into China's vast healthcare market, which serves 1.4 billion people. The study will compare TAEUS against MRI-PDFF in 75 patients, enhancing clinical evidence for commercialization.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. Eastern Time on ENDRA's website. ENDRA is known for its innovative technology, Thermo Acoustic Enhanced UltraSound (TAEUS®), which offers a cost-effective alternative to MRI for visualizing tissues, particularly for assessing liver conditions like NAFLD and NASH affecting over one billion people worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has partnered with King's College Hospital in London for a clinical study to assess the effectiveness of its TAEUS® ultrasound device in diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This seventh clinical research partnership aims to compare TAEUS® with the standard MRI method, targeting 75 patients to enhance data diversity. The study will also provide clinical feedback to support ongoing commercialization of TAEUS®, which is already cleared for sale in Europe and has a pending FDA application.
ENDRA Life Sciences (NASDAQ: NDRA) has signed a collaboration agreement with VGI Health Technology to incorporate its TAEUS technology in VGI's upcoming Phase 2 study of IVB001 for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). This partnership aims to enhance patient screening and biomarker measurement, offering potential cost savings and efficiencies in clinical trial execution. VGI highlights the importance of capturing hepatic steatosis data to improve understanding of NAFLD-NASH, furthering their innovative approach in addressing these conditions.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents by the U.S. Patent and Trademark Office. The patents include U.S. Patent No. 11172829, which enhances thermoacoustic imaging by reducing false signals, and U.S. Patent No. 11176848, which allows for a single phantom for multiple imaging modalities. These patents, the 22nd and 23rd for ENDRA, support the company's strategy to expand the applications of its TAEUS® technology, designed to assess liver conditions affecting over one billion people worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its Q3 2021 results, reporting a net loss of $2.7 million, or $0.06 per share, improved from a loss of $3.3 million, or $0.15 per share, in Q3 2020. Operating expenses decreased to $2.7 million from $3.3 million, aided by reduced spending on product development. The company reported cash reserves of $11.8 million. Clinical studies at UPMC and RVUCOM are underway, focusing on TAEUS system liver fat measurements versus MRI-PDFF. ENDRA also strengthened its patent portfolio with new U.S. patents.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will announce its third-quarter financial results on November 15, 2021, after the market close. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss results and recent developments. Investors can pre-register for the call or access a webcast via the company's Investor Relations page. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), aiming to provide cost-effective diagnostic imaging, particularly for liver conditions affecting over one billion people globally.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted U.S. Patent 11147067, titled “Method And System For Monitoring Tissue Temperature,” enhancing its innovation in Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent complements the earlier U.S. Patent 10631734, both focusing on tissue temperature monitoring during surgical procedures. ENDRA is progressing towards the commercial launch of TAEUS® in Europe and awaits FDA regulatory response for the U.S. market, while its intellectual property portfolio expands to 87 patents, crucial for its strategy in addressing unmet medical needs.
